<code id='DD1E984424'></code><style id='DD1E984424'></style>
    • <acronym id='DD1E984424'></acronym>
      <center id='DD1E984424'><center id='DD1E984424'><tfoot id='DD1E984424'></tfoot></center><abbr id='DD1E984424'><dir id='DD1E984424'><tfoot id='DD1E984424'></tfoot><noframes id='DD1E984424'>

    • <optgroup id='DD1E984424'><strike id='DD1E984424'><sup id='DD1E984424'></sup></strike><code id='DD1E984424'></code></optgroup>
        1. <b id='DD1E984424'><label id='DD1E984424'><select id='DD1E984424'><dt id='DD1E984424'><span id='DD1E984424'></span></dt></select></label></b><u id='DD1E984424'></u>
          <i id='DD1E984424'><strike id='DD1E984424'><tt id='DD1E984424'><pre id='DD1E984424'></pre></tt></strike></i>

          focus

          focus

          author:hotspot    Page View:754
          Judge's gavel
          Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

          WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

          Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

          advertisement

          Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Wikipedia

          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more
          Insitro, AI biotech unicorn, brings cash, new research to JPM 2024
          Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

          DaphneKoller,earlybiotechAIentrantInsitro'sfounder,CEOandboardmember.CourtesyJerrickMitra/InsitroNew

          read more
          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more

          Antibiotic resistance and the global rise in human conflict

          ApatientwithcrutcheswalkpasttheskeletonofahospitaldestroyedbyaRussianattack.EvgeniyMaloletka/APInrec